DNDI Strategy

What is DNDi doing to address unmet treatment needs?

Short term: better use of existing treatments through new formulations
 Paediatric strength of benznidazole: first treatment designed specifically for children

Medium term: development of new treatments through therapeutic switching and combination therapy
 Azoles: clinical development of a well-known compounds already developed against fungal infections for use as Chagas disease monotherapy and/or in combination with existing drugs

Long term: new drugs, and improved research & treatment capacity across region
 Nitroimidazoles: a well-known class of anti-infective compounds
 New drugs developed from promising compounds identified in discovery activities (such as GSK library of pyridones and cysteine protease inhibitors) and progressed through Chagas lead optimisation consortium
 A multi-country, multi-partner Chagas clinical research platform in preparation

By 2014, DNDi aims to deliver from its Chagas-specific portfolio:
1 new paediatric strength available, 1 new drug registered and a robust pipeline.